FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Recombinant patents



      
           
This page is updated frequently with new Recombinant-related patent applications. Subscribe to the Recombinant RSS feed to automatically get the update: related Recombinant RSS feeds. RSS updates for this page: Recombinant RSS RSS


Recombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders

Date/App# patent app List of recent Recombinant-related patents
08/14/14
20140230082
 Recombinant constructs and transgenic fluorescent ornamental fish therefrom patent thumbnailRecombinant constructs and transgenic fluorescent ornamental fish therefrom
The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing.
08/14/14
20140228301
 Recombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders patent thumbnailRecombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders
In one aspect, the disclosure relates to compositions comprising alpha-1-antitrypsin (aat) and the production thereof. In some embodiments, the aat is recombinantly produced.
08/14/14
20140227786
 Retroviral vector particles and methods for their generation and use patent thumbnailRetroviral vector particles and methods for their generation and use
The present invention relates to methods of host cell transduction utilising ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of friend murine leukaemia virus, in particular the envelope encoded by molecular clone pvc-211 and the host cell may be engineered to recombinantly express the rec1 receptor.
08/14/14
20140227756
 Egvi endoglucanase and nucleic acids encoding the same patent thumbnailEgvi endoglucanase and nucleic acids encoding the same
The present invention provides a novel endoglucanase nucleic acid sequence, designated egl6, and the corresponding egvi amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding egvi, recombinant egvi proteins and methods for producing the same..
08/14/14
20140227744
 Single step liquefaction and saccharification of corn starch using an acidophilic, calcium independent and hyperthermophilic pullulanase patent thumbnailSingle step liquefaction and saccharification of corn starch using an acidophilic, calcium independent and hyperthermophilic pullulanase
Moreover, recombinant tk-pul can be used for single step liquefaction and saccharification of corn starch (without any α-amylase or β-amylase) at ph 4.2 in the absence of calcium.. .
08/14/14
20140227743
 Dna polymerases with increased 3'-mismatch discrimination patent thumbnailDna polymerases with increased 3'-mismatch discrimination
Disclosed are mutant dna polymerases having increased 3′-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods.
08/14/14
20140227350
 Annexin a2 and tissue plasminogen activator for treating vascular disease patent thumbnailAnnexin a2 and tissue plasminogen activator for treating vascular disease
The use of tpa to treat hemorrhagic transformation, neurotoxicity has been limited to short treatment time windows because a high dose of tpa required to generate sufficient amounts of the enzyme plasmin for clot lysis. The present invention combines tpa with recombinant annexin a2 resulting in thrombolysis without hemorrhagic transformation at delayed times after stroke.
08/14/14
20140227323
 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens patent thumbnailRecombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
An immunogenic composition comprising a recombinant protein comprising a bordetella cyaa, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided.
08/14/14
20140227312
 A1 moiety of cholera toxin a subunit as an adjuvant for mucosal and systemic vaccines patent thumbnailA1 moiety of cholera toxin a subunit as an adjuvant for mucosal and systemic vaccines
The present invention relates to cholera toxin cta1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant cta1 fragments conjugated to a polypeptide containing a protein transduction domain or cell-penetrating peptide as an immunomodulator..
08/14/14
20140227310
 Recombinant influenza virus highly expressing ha protein and preparation method and use thereof patent thumbnailRecombinant influenza virus highly expressing ha protein and preparation method and use thereof
A pr8 recombinant influenza virus contains an ha and/or na gene of h1, h3, h4, h5, h6, h7, h9 or h10 subtype influenza virus, and 6 internal genes (pb1, pb2, pa, np, m and ns genes) of pr8 virus, in which the ns and/or np gene have the following mutation sites: the ns2 protein encoded by the ns gene has an e67s point mutation, e74s point mutation, or e67s/e74s point mutation, and the np protein encoded by the np gene has a g132a point mutation.. .
08/14/14
20140227308
Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof
The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several hpv antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (cyaa) protein or of a fragment thereof, wherein said cyaa fragment retains the property of said adenylate cyclase protein to target antigen presenting cells. It also concerns polynucleotides encoding the same.
08/14/14
20140227290
Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
Described is a method for increasing the n-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the n-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (otase) complex, for example, the leishmania major stt3d protein, in the presence of expression of the host cell genes encoding the endogenous otase complex.
08/14/14
20140227253
Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
The present invention relates to antigen binding molecules (abms). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human egfr.
08/14/14
20140227248
Compositions and method for increasing production of recombinant gamma-carboxylated proteins
Methods and cell lines for overexpressing functional gamma-carboxylated proteins are disclosed.. .
08/14/14
20140227236
Hiv-resistant stem cells and uses thereof
Disclosed are recombinant stem cells that are resistant to hiv infection. Also disclosed are their uses in treating aids..
08/07/14
20140223607
Transformation system in camelina sativa
The present invention relates to plant biotechnology and specifically to a method for genetically transforming camelina sativa with agrobacterium-mediated transformation system. It comprises camelina sativa for producing homologous and heterologous recombinant products including oil and protein products and assessing and screening the efficacy of plant transformation.
08/07/14
20140223595
Drought tolerant plants and related constructs and methods involving genes encoding dtp6 polypeptides
Isolated polynucleotides and polypeptides and recombinant dna constructs useful for conferring drought tolerance, compositions (such as plants or seeds) comprising these recombinant dna constructs, and methods utilizing these recombinant dna constructs. The recombinant dna construct comprises a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotide encodes a dtp6 polypeptide..
08/07/14
20140221620
Anti-human p-cadherin (cdh3) recombinant antibody
It is an object to provide a recombinant antibody that is an anti-cdh3 antibody having cytotoxicity on cdh3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in seq id no: 38 that is the extracellular region of human cdh3, and has cytotoxicity against cdh3-expressing cells..
08/07/14
20140221295
Modified binding proteins inhibiting the vegf-a receptor interaction
The present invention relates to binding proteins specific for vascular endothelial growth factor a (vegf-a), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits vegf-axxx (wherein xxx denotes the amino acid length of the vegf-a mature protein) binding to vascular endothelial growth factor receptor 2 (vegfr-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety.
08/07/14
20140221270
Methoxypolyethyleneglycol succinimidyl propionate modified recombinant ganoderma immunoregulatory protein, preparing method and application thereof
Methoxypolyethyleneglycol succinimidyl propionate modified recombinant ganoderma immunoregulatory protein, a preparing method and applications thereof are provided, including: the mpeg-spa modified rlz-8; the method for preparing the mpeg-spa modified rlz-8 comprising: feeding the rlz-8 dimer and the mpeg-spa with the molar ratio of 1:1˜1:6 into a 0.1m phosphate buffer with ph 5.0˜ph 8.0, and stirring by a magnetic stirrer at a room temperature for 1.0˜2.5 h, purifying the product for obtaining a modification product with a purity of 98%; and applications of the mpeg-spa modified rlz-8 in preparation of medicine for treating leukopenia due to chemotherapy. Advantages are as follows: the method for preparing the mpeg-spa modified rlz-8 is simple, and the product is identical; a half-life of the mpeg-spa modified rlz-8 is significantly longer than the half-life of unmodified rlz-8 (illustrated in the fig.
08/07/14
20140220658
Recombinant butyrylcholinesterases and truncates thereof
Isolated nucleic acids encoding polypeptides that exhibit butyrylcholinesterase (bche) enzyme activity are disclosed, along with molecular criteria for preparing such nucleic acids, including codon optimization. Methods of preparing modified and/or truncated bche molecules having selected properties, especially selective formation of monomers, are also described.
08/07/14
20140220648
Recombinant production systems for aromatic molecules
The invention relates to the production of aromatic molecules in prokaryotic and eukaryotic hosts such as e. Coli, yeasts, filamentous fungi, algae, microalgae, other plant cells..
08/07/14
20140220647
Microorganism over-expressing lactic acid transporter gene and having inhibitory pathway of lactic acid degradation, and method of producing lactic acid using the microorganism
A recombinant microorganism comprising a lactic acid (la) transporter, wherein the expression of the la transporter in the recombinant microorganism is increased relative to a parent microorganism, and a method of producing lactic acid using same.. .
08/07/14
20140220645
Down-regulation of a polynucleotide encoding a sou2 sorbitol utilization protein to modify lipid production in microbial cells
Recombinant microbial cells are disclosed herein that comprise (i) a down-regulation of an endogenous polynucleotide sequence encoding sou2 sorbitol utilization protein, and (ii) a polyunsaturated fatty acid (pufa) biosynthetic pathway. The down-regulation of the polynucleotide sequence encoding sou2 sorbitol utilization protein can increase the lipid content of the microbial cells and/or decrease the total amount of sugar alcohols produced by the microbial cells.
08/07/14
20140220644
Improved nitrile hydratase
Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are dna for coding the improved nitrile hydratase, a recombinant vector that contains the dna, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase.
08/07/14
20140220641
Transcription factors for cellulosic enzyme production
Provided herein are methods and compositions for increasing the production of one or more cellulases from a fungal host cell. The disclosure is based, on the surprising discovery that mis-expression of the transcriptional regulator clr-2 in a filamentous fungal cell was able to induce expression of cellulase genes under non-inducing or starvation conditions, resulting in increased secretion of cellulases from the cell.
08/07/14
20140220639
Dna polymerases with increased 3'-mismatch discrimination
Disclosed are mutant dna polymerases having increased 3′-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods.
08/07/14
20140220633
Purification of not-glycosylated polypeptides
The current invention reports a method for the purification of a not-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second chromatography step is not a hydroxylapatite chromatography step in case of polypeptides with an isoelectric point below 6.0, and the third chromatography step can be performed in flow-through mode with polypeptides having a low or high isoelectric point.. .
08/07/14
20140220631
Rapid screening method of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom
Disclosed are a method for rapid screening of suitable translational fusion partners (tfps) capable of inducing expression or secretory production of non-producible proteins, which are difficult to produce in conventional recombinant production methods, from a variety of genetic sources, and protein secretion-inducing tfps obtained using the method.. .
08/07/14
20140220605
Vmp-like sequences of pathogenic borrelia species and strains
The present invention relates to dna sequences encoding vmp-like polypeptides of pathogenic borrelia, the use of the dna sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the dna and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, dna segments and antibodies..
08/07/14
20140220603
Compositions and methods for detecting microbial infections
Provided herein are vaccine compositions for control of trypanosoma cruzi infection and chagas disease. The compositions comprise plasmids encoding o gpi-anchored genes asp-2, tcg-1, tcg2 and tcg4 from trypanosoma cruzi; plasmids encoding cytokines il12 and gm-csf; and plasmids encoding a gene expression system.
08/07/14
20140220595
Competition-based detection assays
Disclosed herein are methods and kits which are useful for detecting presence of an enzyme and the relative amount of glycan associated with the enzyme in a test sample based upon the enzyme's ability to competitively inhibit the binding of a ligand in such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes..
08/07/14
20140220553
Enzymatic conversion of blood group a, b, and ab red blood cells using alpha-n-acetylgalactosaminidases and alpha-galactosidases with unique substrate specificities and kinetic properties
This invention relates to enzymatic removal of type a and b antigens from blood group a, b, and ab reactive cells in blood products, and thereby converting these to non-a and non-b reactive cells. The invention further relates to using unique α-n-acetylgalactosaminidases and α-galactosidases with superior kinetic properties for removing the immunodominant monosaccharides of the blood group a and b antigens and improved performance in enzymatic conversion of red blood cells.
08/07/14
20140220076
Recombinant mistletoe lectin and use thereof as an adjuvant
The invention relates to vaccines that comprise antigens and an adjuvant, and to the use of the adjuvant, wherein the adjuvant is selected from a recombinant mistletoe lectin.. .
08/07/14
20140220075
Multi plasmid system for the production of influenza virus
Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided..
08/07/14
20140220072
Shigella-derived vector and methods of using the same
Recombinant vectors comprising the cell entry region of the shigella ox eiec invasion plasmid are provided, as well as, shigella or eiec strains comprising the recombinant vectors. The vectors provide an improved platform for developing attenuated vaccine strains of shigella or eiec and for delivering other foreign proteins of interest.
08/07/14
20140220062
Conditional replicating cytomegalovirus as a vaccine for cmv
The present invention relates to methods of inducing an immune response to cytomegalovirus (cmv) using a genetically modified cmv that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary cmv infection, infection due to reactivation of a latent cmv and a super-infection of a different strain of cmv that had been previously encountered.
08/07/14
20140220038
Lrp1 as key receptor for the transfer of sterified cholesterol from very-low-density lipoproteins (vldl) to ischaemic cardiac muscle
The invention relates to novel molecules that can modulate one of the mechanisms leading to the massive deposition of cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall, during acute myocardial infarction or other clinical situations involving ischaemia. The invention also shows that the blockage of lrp1 by means of certain agents, including a recombinant expression vector, an rnai, an antibody, a sirna etc., prevents the overaccumulation of esterified cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall exposed to ischaemia.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Recombinant for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Recombinant with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3468

4177

3 - 0 - 87